ReviewiScience2026
Brain-derived neurotrophic factor in diabetes: A promising target for cognitive restoration.
Review in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brain-derived neurotrophic factor (BDNF) plays an essential role in neuronal growth and maturation, as well as in maintaining synaptic plasticity. Dysregulated BDNF levels significantly increase the risk of neurological and metabolic disorders. In type 2 diabetes mellitus, several pathological mechanisms, including prolonged hyperglycemia, oxidative damage, chronic inflammation, and impaired insulin sensitivity, are known to drive neurodegenerative processes and deterioration of cognitive function. Impaired BDNF signaling can result in compromised synaptic transmission and gradual loss of neurons, with the hippocampus being particularly vulnerable. A growing body of evidence points to a strong correlation between diminished BDNF levels and diabetes related cognitive decline. Findings from both human clinical trials and animal studies have consistently reported reduced BDNF concentrations in brain tissues and systemic circulation in diabetic conditions. Therapeutic strategies aimed at upregulating BDNF expression and modulating its downstream signaling pathways hold considerable promise for preventing or mitigating diabetes associated cognitive deficits.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.